HLS Therapeutics Inc (74D) Price & Analysis

0 Followers

74D Stock Chart & Stats

€2.26

-€0.06(-2.48%)

At close: Jul 24 4:00 PM EDT

€2.26

-€0.06(-2.48%)

Day’s Range― - ―

52-Week Range€2.04 - €3.26

Previous CloseN/A

Volume0.00

Average Volume (3M)0.00

Market Cap

€89.09M

Enterprise Value€177.89M

Total Cash (Recent Filing)€13.71M

Total Debt (Recent Filing)€41.84M

Price to Earnings (P/E)―

Beta0.04

Next Earnings

Nov 12, 2026

EPS Estimate

-0.06

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.27

Shares Outstanding30,935,060

10 Day Avg. Volume0

30 Day Avg. Volume0

Financial Highlights & Ratios

PEG Ratio0.25

Price to Book (P/B)1.80

Price to Sales (P/S)1.96

P/FCF Ratio7.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€5.28

Price Target Upside133.56% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)-0.13

Revenue Forecast (FY)€37.12M

Bulls Say, Bears Say

Bulls Say

Strong Cash GenerationConsistently positive operating and free cash flow gives HLS internal funding capacity while accounting earnings remain negative. This supports debt reduction, product investment, and operating resilience, making the business less dependent on external financing over the next several quarters.

Cardiovascular Portfolio MomentumRapid cardiovascular growth provides a durable expansion engine beyond the existing portfolio. Vascepa is delivering double-digit sales and unit growth, while Nilemdo is gaining prescriptions and payer access, creating a broader base for revenue and margin growth.

Improving Balance SheetMeaningful deleveraging improves financial flexibility and should reduce interest burdens, allowing more cash to support commercialization and growth. Lower debt also strengthens HLS's ability to manage product launches and absorb operating volatility over the medium term.

Bears Say

Persistent Accounting LossesPersistent net losses and negative return on equity show that HLS has not yet converted its healthy EBITDA and cash generation into sustainable bottom-line profitability. This limits earnings quality and could constrain capital allocation if losses continue across coming reporting periods.

U.S. Clozaril PressureDeclining U.S. Clozaril revenue and an expectation of flat sales indicate that an established product is unlikely to provide near-term growth support. Continued weakness places more importance on successful cardiovascular launches to offset pressure in the existing portfolio.

Margin Pressure From Launch CostsNilemdo commercialization is currently consuming investment before its revenue scale fully offsets higher expenses. The resulting EBITDA decline demonstrates near-term margin pressure, and sustained spending could delay the point at which portfolio growth translates into stronger overall profitability.

HLS Therapeutics Inc News

HLS Therapeutics Sets November 12 Date for Q3 2026 Results Call

HLS Therapeutics Inc ( ($TSE:HLS) ) has issued an announcement. HLS Therapeutics Inc. announced that it will release...

3d ago

HLS Therapeutics CEO to Present at Planet MicroCap Toronto Conference

HLS Therapeutics Inc ( ($TSE:HLS) ) just unveiled an update. HLS Therapeutics Inc. announced that Chief Executive Officer...

5d ago

HLS Therapeutics Revamps Board to Support Next Phase of Growth

HLS Therapeutics Inc ( ($TSE:HLS) ) has issued an announcement. HLS Therapeutics has refreshed its board of directors,...

1M ago

HLS Therapeutics Earnings Call Highlights CV Growth

Hls Therapeutics (($TSE:HLS)) has held its Q2 earnings call. Read on for the main highlights of the call....

2M ago

HLS Therapeutics upgraded to Buy from Hold at Canaccord

Canaccord upgraded HLS Therapeutics (HLTRF) to Buy from Hold with an unchanged price target of C$5. Published first...

3M ago

HLS Therapeutics upgraded to Strong Buy from Outperform at Raymond James

Raymond James upgraded HLS Therapeutics (HLTRF) to Strong Buy from Outperform with a price target of C$8, up...

3M ago

HLS Therapeutics Earns Reiterated Buy Rating from David Martin on Strong 2Q Results and Clozaril Recovery; C$12 Price Target Maintained

David Martin PhD, an analyst from Bloom Burton, maintained the Buy rating on HLS Therapeutics Inc. The associated...

3M ago

Is HLS a Buy, Before Earnings?

Hls Therapeutics (HLS) is scheduled to report 2nd quarter earnings on 08/12/2026, before the market opens. Regarding Q2...

3M ago

HLS Therapeutics resumed with a Hold at Canaccord

Canaccord resumed coverage of HLS Therapeutics (HLTRF) with a Hold rating and C$5 price target Published first on...

6M ago

HLS Therapeutics: Buy Rating Reiterated as Analyst Sees Nilemdo Upside with Unchanged $12 Price Target

Analyst David Martin PhD from Bloom Burton maintained a Buy rating on HLS Therapeutics Inc and keeping the...

6M ago

HLS Earnings this Week: How Will it Perform?

Hls Therapeutics (HLS) is scheduled to report 1st quarter earnings on 05/15/2026, before the market opens. Regarding Q1...

6M ago

HLS Therapeutics to Highlight CNS and Cardiovascular Portfolio at Bloom Burton Investor Conference

HLS Therapeutics Inc ( ($TSE:HLS) ) has shared an announcement. HLS Therapeutics Inc. will showcase its strategy and...

7M ago

HLS Therapeutics: Near-Term Softness Masking NILEMDO-Driven Growth Upside, Supporting Buy Rating

HLS Therapeutics Inc, the Healthcare sector company, was revisited by a Wall Street analyst on March 13. Analyst...

8M ago

HLS Therapeutics price target lowered to C$4.45 from C$4.75 at Stifel

Stifel lowered the firm’s price target on HLS Therapeutics (HLTRF) to C$4.45 from C$4.75 and keeps a Hold...

8M ago

74D FAQ

What was HLS Therapeutics Inc’s price range in the past 12 months?

HLS Therapeutics Inc lowest stock price was €2.04 and its highest was €3.26 in the past 12 months.

What is HLS Therapeutics Inc’s market cap?

HLS Therapeutics Inc’s market cap is €89.09M.

When is HLS Therapeutics Inc’s upcoming earnings report date?

HLS Therapeutics Inc’s upcoming earnings report date is Nov 12, 2026 which is in 11 days.

How were HLS Therapeutics Inc’s earnings last quarter?

HLS Therapeutics Inc released its earnings results on Aug 12, 2026. The company reported -€0.027 earnings per share for the quarter, beating the consensus estimate of -€0.071 by €0.045.

Is HLS Therapeutics Inc overvalued?

According to Wall Street analysts HLS Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does HLS Therapeutics Inc pay dividends?

HLS Therapeutics Inc does not currently pay dividends.

What is HLS Therapeutics Inc’s EPS estimate?

HLS Therapeutics Inc’s EPS estimate is -0.06.

How many shares outstanding does HLS Therapeutics Inc have?

HLS Therapeutics Inc has 30,935,060 shares outstanding.

What happened to HLS Therapeutics Inc’s price movement after its last earnings report?

HLS Therapeutics Inc reported an EPS of -€0.027 in its last earnings report, beating expectations of -€0.071. Following the earnings report the stock price went down -2.679%.

Which hedge fund is a major shareholder of HLS Therapeutics Inc?

Currently, no hedge funds are holding shares in DE:74D

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

HLS Therapeutics Inc Stock Smart Score

Neutral

Fundamentals

Return on Equity

-14.43%

Trailing 12-Months

Asset Growth

-10.34%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

HLS Therapeutics Inc

HLS Therapeutics Inc. operates as a specialized pharmaceutical firm, concentrating on the acquisition and commercialization of medicinal products, primarily within the niche central nervous system (CNS) and cardiovascular (CV) sectors. Its reach extends across Canada, the United States, and international markets. The company's core product lineup includes Clozaril, an atypical antipsychotic used in the treatment of schizophrenia; Vascepa, an icosapent ethyl capsule formulation; and PERSERIS, an injectable risperidone product for treating schizophrenia. Additionally, HLS offers MyCare psychiatry laboratory assays and MyCare Insite tests for point-of-care therapeutic drug-level monitoring. Furthermore, the company possesses U.S. marketing privileges for Absorica, a commercial-stage dermatology solution, and Canadian rights for Trinomia, a cardiovascular therapeutic. It also manages a portfolio of royalty interests from four distinct healthcare products. Founded in 2018, HLS Therapeutics Inc. is based in Etobicoke, Canada.

HLS Therapeutics Inc (74D) Earnings & Revenues

Historic Earnings Reports

74D Stock 12 Month Forecast

Average Price Target

€5.28

▲(133.56% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"€1","8":"€8","2.75":"€2.75","4.5":"€4.5","6.25":"€6.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":7.70093172,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€7.70</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.27834694975,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€5.28</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.8557621795,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€2.86</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,2.75,4.5,6.25,8],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.24,2.660071670769231,3.0801433415384616,3.5002150123076925,3.920286683076923,4.340358353846154,4.760430024615385,5.180501695384615,5.600573366153846,6.020645036923077,6.4407167076923075,6.860788378461538,7.280860049230769,{"y":7.70093172,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.24,2.4737189961346155,2.707437992269231,2.941156988403846,3.1748759845384615,3.408594980673077,3.6423139768076926,3.876032972942308,4.109751969076923,4.343470965211539,4.5771899613461535,4.81090895748077,5.044627953615385,{"y":5.27834694975,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.24,2.2873663215000004,2.334732643,2.3820989645000004,2.429465286,2.4768316075000003,2.524197929,2.5715642505000003,2.618930572,2.6662968935,2.713663215,2.7610295365,2.808395858,{"y":2.8557621795,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.4,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.22,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.86,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.76,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.58,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.6,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.6,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.74,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.66,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.52,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.4,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.14,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.24,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >